Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
IPO Year: 2021
Exchange: NASDAQ
Website: lucirahealth.com
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
William Blair downgraded Lucira Health from Market Outperform to Market Perform
BofA Securities downgraded Lucira Health from Neutral to Underperform and set a new price target of $9.00
William Blair initiated coverage of Lucira Health with a rating of Outperform
Bank of America initiated coverage of Lucira Health with a rating of Neutral and set a new price target of $22.00
William Blair initiated coverage of Lucira Health with a rating of Outperform
BofA Securities initiated coverage of Lucira Health with a rating of Neutral and set a new price target of $22.00
Fastest customizable press release news feed in the world
Lab-quality results for both COVID-19 and Flu now available at home from one single testCOVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access time-sensitive prescription treatment optionsLucira's COVID-19 & Flu Home Test demonstrated similar performance for COVID-19, Flu A and Flu B in head-to-head comparison study with highly sensitive lab-based PCR testsLucira seeks a strategic or financial partner for resumption of manufacturing and development of additional home diagnostic products EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health" or "Lucira"), a medical technology company,
EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company, announced today that it has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. Lucira Health grew rapidly over the past several years as the COVID-19 pandemic spread throughout the world. Demand for the Company's COVID-19 test kits surged and the Company p
New partnership enables a free Sesame telehealth consultation with purchase of a Lucira at-home COVID-19 test, providing a full test-to-treat experience from the comfort of home, within two hours NEW YORK , Jan. 5, 2023 /PRNewswire/ -- Sesame, the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans, and Lucira Health, Inc. ("Lucira Health" or "Lucira") today announced their national partnership to increase access to high-quality, convenient and affordable COVID-19 testing and treatment. Via Lucira Connect, a recently-launched virtual care platform, patients who purchase Lucira's COVID-19 Test can now easily learn about treatment opt
For $98 CAD Canadians will receive a free telehealth appointment included with purchase of a testLucira Connect provides lab-quality at-home test-users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only the cost of the test, excluding prescription costs.Lucira partners with Medi-Call to give users who test positive for Covid-19 or Flu the option to access a virtual telehealth consultation to discuss their risk factors and appropriate treatment options with an independent medical professional. EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health" or "Lucira"), a medical technology company, today anno
EMERYVILLE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health" or "Lucira"), a medical technology company, announced that it submitted an Emergency Use Authorization application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test. Lucira's test for COVID-19 & Flu was granted Emergency Use Authorization for Point-of-Care (POC) use in a healthcare setting in November 2022. In seeking OTC authorization, Lucira intends to make the test broadly available to consumers both online as well as in pharmacies. Lucira worked closely with the FDA to complete additional testing to demonstrate that the COVID & Flu test could be used by con
Lucira COVID-19 & Flu Test is the first and only combination over-the-counter (OTC) self-test with fast, molecular lab-quality results enabling mass testing of symptomatic residents, staff and visitors amid the aggressive COVID-19 and flu season in Canada.Lucira's 99% accurate, differential molecular test can detect Influenza A/B and all strains of COVID-19 earlier in an infection.On-site assessment (as little as 11-mins for positive status up to 30-min for result confirmation) will minimize result turnaround time and improve resident health management pathways at Loch Lomond Villa. EMERYVILLE, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health"
PCR Lab-quality NAAT/molecular test for both COVID-19 and flu from 1 shallow nasal swabPositive result as quickly as 11 minutes, negative result in 30 minutes, allowing diagnosis during patient visitEquipment-free Lucira platform requires no capital investment or calibration and permits unlimited simultaneous testingCOVID-19 and flu have similar symptoms but different treatments, requiring a fast differential test to access time-sensitive prescription treatment options Lucira's COVID-19 & Flu Test performed comparably in a head-to-head comparison study with highly sensitive lab-based PCR tests EMERYVILLE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucir
Digital health service offers Lucira lab-quality at-home test users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only $29, excluding prescription costsLucira partners with Pfizer to increase awareness of the high risk factors for severe COVID-19 and treatment options through the Lucira Connect platform EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (NASDAQ:LHDX) today announced the launch of Lucira Connect, a new virtual care program that allows Lucira test users the ability to test, learn about treatment options, access a telehealth consultation, and if appropriate, receive a prescriptio
EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the third quarter ended September 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $34.4 million for the third quarter of 2022, an increase of 130% over the third quarter of 2021.Executed a marketing agreement with Pfizer to increase awareness of the risks of COVID-19 and the availability of treatment. Partnered with telehealth marketplace, Sesame Care
EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsInvestors interested in listening to the conference call should reg
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
15-12G - Lucira Health, Inc. (0001652724) (Filer)
8-K - Lucira Health, Inc. (0001652724) (Filer)
NT 10-Q - Lucira Health, Inc. (0001652724) (Filer)
S-8 POS - Lucira Health, Inc. (0001652724) (Filer)
S-8 POS - Lucira Health, Inc. (0001652724) (Filer)
8-K - Lucira Health, Inc. (0001652724) (Filer)
NT 10-Q - Lucira Health, Inc. (0001652724) (Filer)
8-K - Lucira Health, Inc. (0001652724) (Filer)
8-K - Lucira Health, Inc. (0001652724) (Filer)
NT 10-K - Lucira Health, Inc. (0001652724) (Filer)
Live finance-specific insights
EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the third quarter ended September 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $34.4 million for the third quarter of 2022, an increase of 130% over the third quarter of 2021.Executed a marketing agreement with Pfizer to increase awareness of the risks of COVID-19 and the availability of treatment. Partnered with telehealth marketplace, Sesame Care
EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsInvestors interested in listening to the conference call should reg
EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the second quarter ended June 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $26.1 million for the second quarter of 2022, an increase of 110% over the second quarter of 2021Received regulatory approval in Canada for the COVID-19 & Flu test with Self Test at Home indication and a full exemption by the New Zealand Ministry of Health for COVID-19 testSc
EMERYVILLE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second quarter 2022 financial results on, Monday, August 15, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or
EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results and provided business updates for the first quarter ended March 31, 2022. Recent Highlights Achieved net revenue of $90.5 million for the first quarter of 2022, equivalent to 97% of fiscal year 2021 net revenueRecorded first-time net income of $13.1 million Entered into a debt facility agreement up to $80 million with Silicon Valley Bank and Hercules Capital; drew down first tranche of $30
EMERYVILLE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report first quarter 2022 financial results on Thursday, May 12, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsThe conference call can be accessed by dialing (833) 562-0151 for participants in the U.S. or Canada and (661) 567-1232 for international cal
EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights Achieved net revenue of $61.1 million for the fourth quarter of 2021, representing approximately 300% sequential growth over the preceding quarterRecorded full year revenue of $93.1 million for 2021, the Company's first full year of commercializationIncreased manufacturing output through the Dominican Repu
EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (NASDAQ:LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report fourth quarter 2021 financial results on, Thursday, March 10, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsThe conference call can be accessed by dialing (833) 562-0151 for participants in the U.S. or Canada and (661) 567-1232 for
EMERYVILLE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the third quarter ended September 30, 2021 and provided business updates. Highlights Recorded record-high revenue of $15.0 million for the third quarter of 2021, representing 21% sequential growth from the previous quarter of 2021Reopened online sales of its OTC LUCIRA CHECK IT COVID-19 Test Kit via the Company's website and on AmazonReceived Pandemic Special Access Route ("PSAR")
EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report third quarter 2021 financial results on, Thursday, November 11, 2021. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsThe conference call can be accessed by dialing (833) 562-0151 for participants in the U.S. or Canada and (661) 567-1232 for internationa
This live feed shows all institutional transactions in real time.
SC 13D/A - Lucira Health, Inc. (0001652724) (Subject)